Inovio Pharmaceuticals Inc vs SOLAI Limited — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Inovio Pharmaceuticals Inc is far larger — about 5.3× SOLAI Limited's market cap. Which is the better fit depends on your goals.
| INO | SLAI | |
|---|---|---|
Market Cap | $89.27M | $16.69M |
Sector | Health | Technology |
52-Week High | $2.87 | $26.74 |
52-Week Low | $1.05 | $2.74 |
Enterprise Value | $60.28M | $16.33M |
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →